Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sisram MedicalSRAMF -87.41%87 Intrinsic Value: Projected FCF is $0.26 as of Sep. 21, 2026. GuruFocus rates SRAMF with a GF Score™ of 87/100 and a GF Value™ of $1.00 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 413 Medical Devices & Instruments companies, Sisram Medical ranks better than 97.58% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-21), Sisram Medical's Intrinsic Value: Projected FCF is $0.26. The stock price of Sisram Medical is $0.0552. Therefore, Sisram Medical's Price-to-Intrinsic-Value-Projected-FCF of today is 0.2.
The historical rank and industry rank for Sisram Medical's Intrinsic Value: Projected FCF or its related term are showing as below:
SRAMF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.21 Med: 0.52 Max: 1.1
Current: 0.21
During the past 11 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Sisram Medical was 1.10. The lowest was 0.21. And the median was 0.52.
SRAMF's Price-to-Projected-FCF is ranked better than 97.58% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 1.46
vs SRAMF: 0.21
Sisram Medical (OTCPK:SRAMF) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Sisram Medical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.0552
/
1.5215065451888
=
0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical Intrinsic Value: Projected FCF Related Terms
Sisram Medical Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Sisram Medical's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sisram Medical Intrinsic Value: Projected FCF Chart
SRAMF vs ABT, SYK, MDT: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Sisram Medical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Sisram Medical's Price-to-Projected-FCF falls into.
Sisram Medical Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.26 mean?
Sisram Medical (SRAMF) has a Intrinsic Value: Projected FCF of $0.26 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sisram Medical and its competitors. According to the industry distribution chart, Sisram Medical ranks #10 out of 413 companies in the Medical Devices & Instruments industry, placing it in the top 2.4%.
Is Sisram Medical's Intrinsic Value: Projected FCF too high?
Sisram Medical's current Intrinsic Value: Projected FCF is $0.26. The Medical Devices & Instruments industry median Intrinsic Value: Projected FCF is 1.46. Sisram Medical's value of $0.26 is 82.2% below this industry median. Based on the distribution chart, Sisram Medical ranks #10 out of 413 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sisram Medical has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Intrinsic Value: Projected FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #10 out of 413 companies for Intrinsic Value: Projected FCF. This places Sisram Medical in the top 2% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.46. Sisram Medical's value of $0.26 is 82.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.46, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current Intrinsic Value: Projected FCF of $0.26 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current Intrinsic Value: Projected FCF is $0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.00, compared to a current price of $0.06 — trading 94.5% below its estimated fair value. The current Intrinsic Value: Projected FCF is $0.26 and 82.2% below the Medical Devices & Instruments industry median of 1.46. Sisram Medical's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Intrinsic Value: Projected FCF is $0.26 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.06 is trading 94.5% below its estimated GF Value™ of $1.00.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
Intrinsic Value: Projected FCF: $0.26
GF Value™: $1.00 vs. price of $0.06 (94.5% below fair value)
Industry Position: 82.2% below the Medical Devices & Instruments median (#10 of 413)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
87GF Score
Get the complete analysis for SRAMF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
